Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

U.S. drugmaker Perrigo to buy Ireland's Elan for $8.6 billion

07/29/2013 | 11:10am EDT

DUBLIN (Reuters) - U.S. drugmaker Perrigo (>> Perrigo Company) agreed to buy Elan (>> Elan Corporation, plc) for $8.6 billion (5.6 billion pounds) in a deal that will hand it tax savings from being domiciled in Ireland and royalties from a blockbuster multiple sclerosis treatment.

DUBLIN (Reuters) - U.S. drugmaker Perrigo (>> Perrigo Company) agreed to buy Elan (>> Elan Corporation, plc) for $8.6 billion (5.6 billion pounds) in a deal that will hand it tax savings from being domiciled in Ireland and royalties from a blockbuster multiple sclerosis treatment.

The deal, agreed on Monday, ends a bitter takeover battle in which Elan rejected three lower bids from U.S. investment firm Royalty Pharma <ROYPH.UL> amid injunctions, court hearings and a war of words before putting itself up for sale last month.

Michigan-based Perrigo, which makes over-the-counter pharmaceuticals for the in-store brand market and has a market value of some $12 billion, will pay $6.25 per share in cash plus $10.25 per share in stock, a premium of about 10.5 percent over Elan's closing price on Friday.

Elan <ELN.N> shares rose 3.8 percent on Monday to $15.5, close to a bid that analysts expect will be snapped up by shareholders who rejected Royalty's successive overtures. Perrigo shares dropped 6.7 percent to $125.3

"Elan has uncovered an excellent offer for its shareholders, substantially ahead of the level Royalty Pharma could achieve," Berenberg Biotech analysts said in a note to clients.

For Elan and Chief Executive Kelly Martin, who took over the firm in 2003 when its share price had sunk to $2, the Perrigo deal is vindication for rejecting Royalty's advances.

Martin, a low-key former Merrill Lynch banker, took a series of verbal attacks in a four-month saga that frequently turned ugly.

In an open letter to the Elan board last month, Royalty predicted that Elan was embarking on a lengthy and likely fruitless effort to find a buyer willing to better its offer.

Royalty's final bid was $13 in cash per share as well as a "contingent value right" that could have added a further $2.50 per share if Elan's blockbuster multiple sclerosis drug Tysabri hit certain sales milestones.

According to Deutsche Bank analysts, Perrigo's offer is a significant premium to their $12 per share valuation of Elan, reflecting the tax advantage, and worth about a fifth more than their calculation of the Royalty bid.


Reuters reported exclusively last week that Perrigo and New York-based Forest Laboratories Inc (>> Forest Laboratories, Inc.) were preparing to bid.

Elan is especially appealing for companies like Perrigo that can easily move their headquarters abroad because of the very low 12.5 percent corporate tax rate in Ireland, compared with 35 percent in the United States.

Fellow generic drugmaker Actavis' (>> Actavis Inc) $5 billion acquisition of Dublin-based Warner Chilcott (>> Warner Chilcott Plc) in May allowed it lower its tax rate to 17 percent from 28 percent.

Hundreds of U.S. companies have subsidiaries in Ireland for the same purpose. That practice prompted international criticism after the U.S. Senate revealed that technology giant Apple (>> Apple Inc.) paid little or no tax on tens of billions of dollars in profits channelled through the country.

The Elan deal buys Perrigo a full tax domicile in Ireland, bringing the bulk of its income under the Irish tax regime. It will use $4.35 billion in bridge financing from Barclays and HSBC plus cash to fund the deal, which also brings it Elan's $1.9 billion cash pile.

Perrigo Chief Executive Joe Papa said the acquisition would cut its effective tax rate to 17 percent in the first 12 to 18 months from around 30 percent now. Chief Financial Officer Judy Brown told an analyst call that it may go even lower over time.

"We think it's financially compelling and when you put it together with an Irish domicile that has operational tax synergies, we think it's a really compelling story," Papa told Reuters in a telephone interview.

The Perrigo boss, for whom Elan is the largest of more than a dozen deals he has led since taking over in 2006, said the company remained committed to the United States where it employs over half of its 9,000 workers. It will remain listed in New York and Tel Aviv <PRGO.TA>, he said.

Papa said Ireland would give Perrigo a gateway into the rest of Europe and saw the Tysabri royalty, worth of up to 25 percent on future sales, as a means to fund future opportunities.

Elan sold its 50 percent interest in Tysabri to U.S. partner Biogen Idec (>> Biogen Idec Inc) in February for $3.25 billion but retained royalties in the drug whose sales rose to $1.6 billion in 2012.

Elan, founded as a private company in 1969, also drew initial interest from Allergan Inc (>> Allergan, Inc.), Mylan International (>> Mylan Inc.) and Endo HealthSolutions Inc (>> Endo Health Solutions Inc), several people familiar with the situation have said.

Barclays advised Perrigo on the deal, while Citigroup Global Markets, Davy and Davy Corporate Finance, Morgan Stanley & Co. International and Ondra LLP acted for Elan.

($1 = 0.7539 euros)

(Editing by Tom Pfeiffer and Erica Billingham)

By Padraic Halpin and Sam Cage

© Reuters 2013
Stocks mentioned in the article
ChangeLast1st jan.
APPLE INC. 0.02% 149.3401 Delayed Quote.12.49%
BIOGEN INC. 1.34% 270.53 Delayed Quote.9.50%
ELAN CORPORATION LTD -0.39% 12.71 End-of-day quote.0.00%
HSBC HOLDINGS PLC 0.45% 435.2248 Delayed Quote.14.37%
MORGAN STANLEY 0.26% 100.85 Delayed Quote.46.88%
ROYALTY PHARMA PLC 0.33% 37.54 Delayed Quote.-25.29%
2014FOREST LABORATORIES : Actavis and Forest Receive U.S. FTC Clearance for Actavis' Proposed ..
2014FOREST LABORATORIES : Actavis and Forest Announce Preliminary Stockholder Merger Considera..
2014FOREST LABORATORIES : Announces Positive Topline Results from Three Phase III Trials for V..
2014FOREST LABORATORIES : Actavis and Forest Laboratories Announce Appointment of C. David Nic..
2014FOREST LABORATORIES : to Present Cariprazine Data at the International College of Neuropsy..
2014FOREST LABORATORIES : Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA® and NAMEN..
2014FOREST LABORATORIES : COPD Foundation Releases Groundbreaking COPE Survey Results: Low Pat..
2014FOREST LABORATORIES : Announces Receipt of Requisite Consents and Expiration of Consent So..
2014FOREST LABORATORIES : Announces Intention to Continue Marketing Both NAMENDA® TABLETS and ..
2014FOREST LABORATORIES : Extends Expiration Time of Consent Solicitations to Eliminate Existi..
More news
Analyst Recommendations on FOREST LABORATORIES, INC.
More recommendations
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.07%431 148
ROCHE HOLDING AG13.98%333 101
PFIZER, INC.14.34%239 966
NOVO NORDISK A/S56.26%238 738